Glioblastoma Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight
(Albany, USA) DelveInsight's " Glioblastoma Market Insights, Epidemiology and Market Forecast– 2034" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The Glioblastoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Glioblastoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Glioblastoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Glioblastoma market.
The pipeline review for the glioblastoma treatment market highlights a dynamic landscape of ongoing clinical trials and emerging therapies aimed at addressing this aggressive brain cancer. Several biopharmaceutical companies are actively developing novel approaches, including targeted therapies, immunotherapies, and gene-based treatments. The glioblastoma treatment pipeline also features advancements in personalized medicine and biomarker-driven strategies. This evolving pipeline holds promise for improving patient outcomes and expanding therapeutic options in the coming years.
Key Takeaways from the Glioblastoma Market Report
The increase in Glioblastoma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
As per DelveInsight analysis, the Glioblastoma Market is anticipated to witness growth at a considerable CAGR.
The leading Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.
Promising Glioblastoma Pipeline Therapies in the various stages of development include ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
In May 2025, CNS Pharmaceuticals Inc. announced a study that is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria.
In May 2025, In8bio Inc . Conducted a Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.
In April 2025, Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology.
In December 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food and Drug Administration (FDA).
On October 15, 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for the treatment of glioblastoma (GBM). LP-184 induces tumor cell death through DNA damage and is currently in a Phase 1a trial assessing its safety and tolerability in patients with various solid tumors, including GBM. The Fast Track status aims to accelerate the development and review of LP-184, particularly given the limited treatment options for aggressive brain cancers like GBM.
April 2024:- Boston Scientific Corporation- FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM. Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in <7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.
April 2024:- TJ Biopharma Co., Ltd. - A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT). A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT).
Stay ahead in oncology R&D with our latest pipeline review glioblastoma treatment market overview, covering immunotherapies and targeted agents, visit @ Glioblastoma Treatment Market Landscape
Glioblastoma Overview
Glioblastoma (GBM) is an aggressive and the most common primary malignant brain tumor in adults. Classified as a grade IV astrocytoma by the World Health Organization, it originates from astrocytes, the supportive glial cells in the brain. GBM is characterized by rapid growth, extensive infiltration into surrounding brain tissue, and significant heterogeneity at the cellular and molecular levels.
Patients often present with neurological symptoms such as headaches, seizures, cognitive decline, or focal deficits, depending on the tumor's location. Diagnosis typically involves magnetic resonance imaging (MRI) and confirmation via biopsy or surgical resection, which also serves as an initial treatment step.
Standard treatment includes maximal safe surgical resection, followed by concurrent radiotherapy and temozolomide chemotherapy. Despite aggressive multimodal therapy, GBM remains highly resistant to treatment, with a median survival of 15–18 months. Recurrence is almost inevitable, and treatment options for recurrent disease are limited.
Molecular profiling of GBM, including markers like MGMT promoter methylation and IDH mutation status, guides prognosis and treatment decisions. Emerging therapies, such as tumor-treating fields (TTFs), immunotherapy, and targeted molecular inhibitors, are under investigation. While these advances offer hope, GBM remains a formidable challenge, highlighting the urgent need for innovative therapies.
Glioblastoma Epidemiology Insights
The epidemiology section of Glioblastoma offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Glioblastoma Epidemiology trends @ Glioblastoma Epidemiological Insights
Glioblastoma Drugs Market
The Glioblastoma Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Glioblastoma signaling in Glioblastoma are likely to uncover new therapeutic targets and further expand treatment options for patients.
Glioblastoma Treatment Market Landscape
The Glioblastoma treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Glioblastoma has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
Glioblastoma Market Outlook
The report's outlook on the Glioblastoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glioblastoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glioblastoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glioblastoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Glioblastoma Drugs Uptake
The drug chapter of the Glioblastoma report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Glioblastoma.
A comprehensive pipeline review glioblastoma treatment market analysis reveals promising investigational drugs and upcoming clinical trial milestones.
Major Glioblastoma Companies
Several Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.
Scope of the Glioblastoma Market Research Report
Coverage- 7MM
Glioblastoma Companies- Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.
Glioblastoma Pipeline Therapies- ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
Glioblastoma Market Dynamics: Glioblastoma Market Drivers and Barriers
Glioblastoma Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Glioblastoma Drugs in development @ Glioblastoma Clinical Trials and FDA Approvals
Table of Content
1. Key Insights
2. Report Introduction
3. Glioblastoma Multiforme Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary of Glioblastoma Multiforme (GBM)
6. Key Events
7. Glioblastoma SWOT Analysis
8. Disease Background and Overview: Glioblastoma Multiforme
9. Glioblastoma Treatment
10. Guidelines and Recommendations from Different Organizations
11. Glioblastoma Epidemiology and Patient Population
12. Glioblastoma Patient Journey
13. Key Endpoints in Glioblastoma Multiforme
14. Glioblastoma Marketed Products
15. Emerging Glioblastoma Drugs
16. Glioblastoma Market: Seven Major Market Analysis
17. Glioblastoma KOL Views
18. Glioblastoma Unmet Needs
19. Glioblastoma Market Access and Reimbursement
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
14 minutes ago
- CBC
LeBlanc says he expects Carney, Trump to talk 'over the next couple of days'
Social Sharing Dominic LeBlanc says he expects Prime Minister Mark Carney and U.S. President Donald Trump will have a conversation with each other "over the next couple of days" as Canada tries to find a way out of a 35 per cent blanket tariff on exports to the U.S. "We believe there's a great deal of common ground between the United States and Canada in terms of building two strong economies that work well together," said LeBlanc, the minister responsible for Canada-U.S. trade, on CBS's Face The Nation. LeBlanc left Washington earlier this week without a deal, but he told host Margaret Brennan he came out of discussions "with a better understanding of the American concerns in the trading relationship…. So we're prepared to stick around and do the work needed." Few Canadian goods subject to new rate On Friday just after midnight, Canada's tariff rate rose to 35 per cent following a Trump executive order that criticized Canada's "lack of co-operation" in curbing the flow of fentanyl southward and for retaliating against Trump's existing tariffs. But only a very small number of Canadian products will actually be subjected to that rate — specifically goods not covered by the Canada-U.S.-Mexico Agreement, which governs trade between the three countries. WATCH | LeBlanc insists there wasn't a good deal before Trump's Aug. 1 deadline: No trade deal with U.S. better than a bad one, LeBlanc says 2 days ago LeBlanc told Brennan that Canada was "obviously disappointed" by Trump's decision to raise the tariff rate. In a separate interview on Face The Nation, U.S. Trade Representative Jamieson Greer said Canada was the only country aside from China to retaliate against Trump's tariffs. "If the president is going to take an action and the Canadians retaliate, the United States needs to maintain the integrity of our action — the effectiveness — so we have to go up," Greer told Evans. Trump tariffs face legal challenge When asked whether Canada should drop its countertariffs, LeBlanc cited Ottawa's 25 per cent countertariff on U.S. steel and aluminum imports. "There's a 50 per cent tariff when we want to sell [steel] into the United States, so effectively we're blocked from doing that. But the national security interest of Canada requires we have a viable steel and aluminum sector." Trump invoked his 35 per cent levy using a law that allows the U.S. president to take emergency economic measures to "deal with any unusual and extraordinary threat" to national security. That tariff is facing a legal challenge that has now reached a federal appeals court, putting it further along in the U.S. court system than any other tariff lawsuit.
Globe and Mail
38 minutes ago
- Globe and Mail
3 Top REIT Dividend Stocks to Buy in August for Passive Income
Key Points Mid-America Apartment Communities has increased its dividend for 15 years in a row. Invitation Homes has raised its payment every year since it went public. Realty Income has one of the best dividend growth streaks in the REIT sector. 10 stocks we like better than Realty Income › Investing in real estate investment trusts (REITs) is a great way to generate passive dividend income. Most REITs own large portfolios of income-generating real estate, which provide them with the cash flow to pay attractive dividends. Mid-America Apartment Communities (NYSE: MAA), Invitation Homes (NYSE: INVH), and Realty Income (NYSE: O) are three top REITs due to their consistent dividend growth, strong financial profiles, and high-quality portfolios. Those features make them great stocks to buy for passive income this August. Capitalizing on growing apartment demand Mid-America Apartment Communities has an excellent record of paying dividends. The landlord recently declared its 126th consecutive quarterly dividend. It pays $6.06 per share each year, giving it a more than 4% yield at its recent share price. Mid-America has never reduced or suspended its dividend in its more than 30 years as a public company and has raised the payout for 15 years in a row. The REIT should have no trouble continuing to increase its dividend. Demand for apartments in the Sun Belt region where it operates is strong and growing, while new supplies should be limited in the future. That should keep occupancy levels high across its portfolio and drive steady rent growth. Meanwhile, Mid-America Apartment Communities currently has nearly $1 billion of apartment development projects underway that it expects to complete over the next few years. It also recently completed four projects and acquired two new communities in the lease-up phase for nearly $575 million. "The strengthening demand/supply dynamic coupled with our growing development pipeline, which is nearing $1 billion, should support robust revenue and earnings performance and enhance long-term value creation," stated CEO Brad Hill in the REIT's recent second-quarter earnings report. Cashing in on demand for rental housing Invitation Homes stands out for its consistent dividend record. Since its initial public offering in 2017, this REIT, which specializes in single-family rental homes, has increased its payout each year. The current dividend is $0.29 per share quarterly ($1.16 annually), giving it a yield approaching 4% at the most recent share price. The REIT owns and manages single-family rental properties in high-demand housing markets. That drives healthy rent growth (4% in the second quarter). Additionally, Invitation Homes steadily invests capital to grow its rental property portfolio. It spent $350 million to buy over 1,000 homes in the second quarter. The REIT also provided a developer with $33 million in funding to build a 156-home community that it can acquire in the future. These investments are providing it with incremental sources of income to support its steadily rising dividend. The name says it all Realty Income has one of the best dividend track records in the REIT sector. The company has increased its monthly dividend 131 times since its public market listing in 1994, including the past 111 straight quarters. At the REIT's current payment level ($0.269 per share a month and $3.228 annually), it has a yield approaching 6%. The diversified REIT backs that payout with very stable rental income. It leases its retail, industrial, gaming, and other properties to many of the world's leading companies under long-term triple-net (NNN) agreements. Those leases require that tenants cover all property operating costs, including routine maintenance, real estate taxes, and building insurance. Realty Income also has a very strong financial profile. That gives it the flexibility to continue acquiring properties secured by long-term net leases. It currently expects to invest about $4 billion this year to expand its portfolio. These new investments will enable the REIT to continue increasing its high-yielding monthly dividend. High-quality, high-yielding REITs Mid-America Apartment Communities, Invitation Homes, and Realty Income pay high-yielding and steadily rising dividends. With more growth ahead, they're great REITs to buy this month to collect a rising stream of passive dividend income. Should you invest $1,000 in Realty Income right now? Before you buy stock in Realty Income, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Realty Income wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
National Post
43 minutes ago
- National Post
U.S. trade advisor says Trump tariff rates unlikely to change
New U.S. tariff rates are 'pretty much set' with little immediate room for negotiation, Donald Trump's trade advisor said in remarks aired Sunday, also defending the president's politically driven levies against Brazil. Article content Trump, who has wielded tariffs as a tool of American economic might, has set tariff rates for dozens of economies including the European Union at between 10 and 41 percent come August 7, his new hard deadline for the duties. Article content Article content Article content In a pre-taped interview broadcast Sunday on CBS's 'Face the Nation,' US Trade Representative Jamieson Greer said 'the coming days' are not likely to see changes in the tariff rates. Article content Article content 'A lot of these are set rates pursuant to deals. Some of these deals are announced, some are not, others depend on the level of the trade deficit or surplus we may have with the country,' Greer said. Article content 'These tariff rates are pretty much set.' Article content Undoubtedly some trade ministers 'want to talk more and see how they can work in a different way with the United States,' he added. But 'we're seeing truly the contours of the president's tariff plan right now with these rates.' Article content Last Thursday, the former real estate developer announced hiked tariff rates on dozens of US trade partners. Article content They will kick in on August 7 instead of August 1, which had previously been touted as a hard deadline. Article content Among the countries facing steep new levies is Brazil. South America's largest economy is being hit with 50 percent tariffs on exports to the United States — albeit with significant exemptions for key products such as aircraft and orange juice. Article content Article content Trump has openly admitted he is punishing Brazil for prosecuting his political ally Jair Bolsonaro, the ex-president accused of plotting a coup in a bid to cling to power. The US president has described the case as a 'witch hunt.' Article content Greer said it was not unusual for Trump to use tariff tools for geopolitical purposes. Article content 'The president has seen in Brazil, like he's seen in other countries, a misuse of law, a misuse of democracy,' Greer told CBS. 'It is normal to use these tools for geopolitical issues.' Article content Trump was 'elected to assess the foreign affairs situation … and take appropriate action,' he added. Article content Meanwhile White House economic advisor Kevin Hassett said that while talks are expected to continue over the next week with some US trade partners, he concurred with Greer's tariffs assessment in that the bulk of the rates 'are more or less locked in.' Article content Asked by the host of NBC's Sunday talk show 'Meet the Press with Kristen Welker' if Trump could change tariff rates should financial markets react negatively, Hassett said: 'I would rule it out, because these are the final deals.' Article content An appeals court panel on Thursday appeared skeptical of the government's arguments, though the case may be ultimately decided at the Supreme Court. Article content
